Company & Sponsor Intelligence
Rovi Pharmaceuticals Laboratories
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries1
Therapeutic footprint
schizophrenia
Indexed studies
NCT03527186Comparative Bioavailability of Risperidone
schizophrenia · United StatesPHASE1
schizophrenia · United StatesPHASE1
NCT03870880Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
schizophrenia · United StatesPHASE3
schizophrenia · United StatesPHASE3
NCT05179525Comparative Bioavailability of Risperidone.
schizophrenia · United StatesPHASE1
schizophrenia · United StatesPHASE1
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →